Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. - Powell, Matthew; Zub, Oleksandr; Gilbert, Lucy; Koliadi, Anthoula; Willmott, Lyndsay; Black, Destin; Ronzino, Graziana; Sharma, Sudarshan; Gropp-Meier, Martina; Landrum, Lisa; Thijs, Anna; Lokich, Elizabeth; et al. (Gynecologic Oncology, 2026)